CN102131514B - 用于治疗性功能障碍的黑皮质素受体特异性肽 - Google Patents

用于治疗性功能障碍的黑皮质素受体特异性肽 Download PDF

Info

Publication number
CN102131514B
CN102131514B CN200980129114.3A CN200980129114A CN102131514B CN 102131514 B CN102131514 B CN 102131514B CN 200980129114 A CN200980129114 A CN 200980129114A CN 102131514 B CN102131514 B CN 102131514B
Authority
CN
China
Prior art keywords
peptide
present
cyclic peptide
acid
sexual dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980129114.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102131514A (zh
Inventor
施亦群
舒布赫·D·夏尔马
杨炜
新·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Palatin Technologies Inc
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of CN102131514A publication Critical patent/CN102131514A/zh
Application granted granted Critical
Publication of CN102131514B publication Critical patent/CN102131514B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN200980129114.3A 2008-06-09 2009-06-08 用于治疗性功能障碍的黑皮质素受体特异性肽 Expired - Fee Related CN102131514B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5991008P 2008-06-09 2008-06-09
US61/059,910 2008-06-09
PCT/US2009/046571 WO2009152079A1 (en) 2008-06-09 2009-06-08 Melanocortin receptor-specific peptides for treatment of sexual dysfunction

Publications (2)

Publication Number Publication Date
CN102131514A CN102131514A (zh) 2011-07-20
CN102131514B true CN102131514B (zh) 2014-08-20

Family

ID=41417081

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980129114.3A Expired - Fee Related CN102131514B (zh) 2008-06-09 2009-06-08 用于治疗性功能障碍的黑皮质素受体特异性肽

Country Status (14)

Country Link
US (2) US8487073B2 (enExample)
EP (1) EP2300036B1 (enExample)
JP (1) JP5628796B2 (enExample)
KR (1) KR101687037B1 (enExample)
CN (1) CN102131514B (enExample)
AU (1) AU2009257631B2 (enExample)
BR (1) BRPI0909947A2 (enExample)
CA (1) CA2727317C (enExample)
EA (1) EA018630B1 (enExample)
IL (1) IL209867A (enExample)
MX (1) MX2010013436A (enExample)
NZ (1) NZ590254A (enExample)
WO (1) WO2009152079A1 (enExample)
ZA (1) ZA201009165B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009257631B2 (en) 2008-06-09 2014-07-24 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
CN105037502A (zh) 2009-06-08 2015-11-11 帕拉丁科技公司 黑皮质素受体特异性肽
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011063366A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
KR20120102716A (ko) 2009-11-23 2012-09-18 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴-1 수용체 특이적 선형 펩티드
RS62701B1 (sr) 2011-12-29 2022-01-31 Rhythm Pharmaceuticals Inc Postupak lečenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
CN102702330B (zh) * 2012-03-01 2015-04-01 张嘎 环状核心序列与生物素或穿膜肽相连而成的促黑激素类似物
US9534018B2 (en) 2012-03-13 2017-01-03 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
MX362610B (es) * 2012-11-05 2019-01-28 Palatin Technologies Inc Usos de bremelanotida en terapia para la disfunción sexual femenina.
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
EP3356386B1 (en) 2015-09-30 2024-02-14 Rhythm Pharmaceuticals, Inc. Method of treating melanocortin-4 receptor pathway-associated disorders
RU2655763C2 (ru) * 2016-10-24 2018-05-29 Общество С Ограниченной Ответственностью "Айвикс" Фармацевтическая композиция и способ лечения женских сексуальных дисфункций
AU2019249255A1 (en) 2018-04-06 2020-11-05 Alastair GARFIELD Compositions for treating kidney disease
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
EP4100042A4 (en) * 2020-02-03 2024-04-10 Palatin Technologies, Inc. Reverse amide-linked melanocortin receptor-specific cyclic peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000339A2 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0292291B1 (en) 1987-05-22 1994-08-10 University Patents, Inc. Linear and cyclic analogs of alpha-msh fragments with extraordinary potency
US5674839A (en) * 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6100048A (en) * 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
EP0696919B1 (en) * 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US6054556A (en) * 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US7396814B2 (en) * 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
CA2158425C (en) 1995-09-15 2003-01-28 Mac E. Hadley Diagnostic and treatment of erectile dysfunction
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
AU5348098A (en) 1996-12-17 1998-07-15 Quadrant Holdings Cambridge Limited Melanocortins
WO1999021571A1 (en) 1997-10-27 1999-05-06 Trega Biosciences, Inc. Melanocortin receptor ligands and methods of using same
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
SE9801571D0 (sv) * 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
SE9804614A0 (en) 1998-07-06 2000-01-07 A+ Science Invest Ab New peptides and use thereof
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US6887846B2 (en) * 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
TR200102765T2 (tr) * 1999-03-29 2002-05-21 The Procter & Gamble Company Melanokortin reseptör ligandları
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6699873B1 (en) * 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
US20030064921A1 (en) * 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
EP1251865A1 (en) * 2000-01-18 2002-10-30 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US6600015B2 (en) * 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
AU2001261363A1 (en) 2000-05-09 2001-11-20 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
RU2239642C1 (ru) 2000-08-30 2004-11-10 Ф.Хоффманн-Ля Рош Аг Селективные циклопептиды
AU9631301A (en) 2000-09-27 2002-04-08 Procter & Gamble Melanocortin receptor ligands
US20030113263A1 (en) * 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
ITMI20011057A1 (it) 2001-05-22 2002-11-22 Bracco Imaging Spa Preparazione ed uso di peptidi ciclici e ramificati e loro deriati marcati come agenti terapeutici agonisti o antagonisti della colecistochi
JP2004534851A (ja) * 2001-07-11 2004-11-18 パラチン テクノロジーズ インク． メラノコルチン受容体に特異的な線状および環状ペプチド
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
WO2003006604A2 (en) 2001-07-12 2003-01-23 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
ES2274201T3 (es) * 2002-01-23 2007-05-16 Eli Lilly And Company Agonistas del receptor de melanocortina.
FR2835528B1 (fr) * 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
AU2003290886A1 (en) 2002-11-14 2004-06-15 Zengen, Inc. Modified alpha-msh peptides and derivatives thereof
US7135548B2 (en) * 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
US20050101535A1 (en) * 2003-05-06 2005-05-12 Rosenstein David H. Use of a synthetic alpha-melanocyte stimulating hormone agonist to decrease steroid induced weight gain
EP1625158A2 (en) 2003-05-09 2006-02-15 Novo Nordisk A/S Peptides for use in treating obesity
MXPA05011830A (es) * 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
US7084111B2 (en) * 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
ES2286679T3 (es) * 2003-08-20 2007-12-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4).
CN100482682C (zh) * 2003-09-30 2009-04-29 诺沃挪第克公司 黑皮素受体激动剂
NZ547383A (en) 2003-11-24 2009-11-27 Clinuvel Pharmaceuticals Ltd A method of inducing melanogenesis in humans with MC1R variant alleles
WO2005060985A1 (en) 2003-12-10 2005-07-07 Merck & Co., Inc. Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
EP1732586A1 (en) * 2004-03-29 2006-12-20 Eli Lilly And Company Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continunous infusion
CN1563076A (zh) 2004-04-02 2005-01-12 西南生物工程产业化中试基地有限公司 一种用于治疗性功能障碍的α－MSH类似物及制备方法
JP5208504B2 (ja) 2004-08-04 2013-06-12 クリヌベール、ファーマスーティカルズ、リミテッド 対象者でメラニン形成を誘導するための方法
TW200626611A (en) 2004-09-20 2006-08-01 Lonza Ag Peptide cyclisation
AU2005291862B2 (en) 2004-10-08 2010-07-08 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
US20060105951A1 (en) * 2004-10-25 2006-05-18 Mark Cunningham Melanocortin receptor binding mimetibodies, compositions, methods and uses
WO2006048449A2 (en) 2004-11-04 2006-05-11 Novo Nordisk A/S Mc4r selective peptides and their use in the treatment of obesity
US20080280820A1 (en) 2004-11-04 2008-11-13 Ulrich Sensfuss Novel Peptides for Use in the Treatment of Obesity
JP2008519007A (ja) 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
EP1809667A1 (en) 2004-11-04 2007-07-25 Novo Nordisk A/S Peptides for use in the treatment of obesity
WO2006060873A1 (en) 2004-12-09 2006-06-15 Prince Henry's Institute Of Medical Research Method for restoring reproductive function
WO2006073771A2 (en) 2005-01-05 2006-07-13 Eli Lilly And Company Polyethylene glycol linked mc4r or mc3r agonist peptides
WO2006076442A2 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
WO2006097526A1 (en) 2005-03-17 2006-09-21 Novo Nordisk A/S Compounds for use in the treatment of obesity
EP1885743A1 (en) 2005-05-31 2008-02-13 Yissum Research Development Company, of The Hebrew University of Jerusalem BACKBONE CYCLIZED MELANOCORTIN STIMULATING HORMONE ( alpha S ) ANALOGS
RU2401841C2 (ru) 2005-07-08 2010-10-20 Ипсен Фарма С.А.С. Лиганды рецепторов меланокортинов
EP3925614A3 (en) 2005-07-08 2022-03-23 Ipsen Pharma Melanocortin receptor ligands
CN1709906A (zh) 2005-07-15 2005-12-21 中国科学技术大学 α－促黑激素的环状类似肽及其应用
MX2007016024A (es) 2005-07-18 2008-03-10 Novo Nordisk As Peptidos novedosos para el uso en el tratamiento contra la obesidad.
US20080227693A1 (en) 2005-08-29 2008-09-18 Palatin Technologies, Inc. Cyclic Peptide Isolation by Spray Drying
WO2007035474A2 (en) 2005-09-15 2007-03-29 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof
AU2006350707A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
JP2010516654A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
EP2106406A2 (en) 2007-01-18 2009-10-07 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
WO2008087187A1 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
FR2914646A1 (fr) 2007-04-04 2008-10-10 Neorphys Soc Par Actions Simpl Analogues peptidiques des recepteurs des melanocortines
WO2008156677A2 (en) 2007-06-15 2008-12-24 Ipsen Pharma S.A.S. Cyclic peptide melanocortin receptor ligands
AR072072A1 (es) 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
AU2009257631B2 (en) * 2008-06-09 2014-07-24 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144341A2 (en) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000339A2 (en) * 2003-06-19 2005-01-06 Eli Lilly And Company Melanocortin receptor 4(mc4) agonists and their uses

Also Published As

Publication number Publication date
AU2009257631B2 (en) 2014-07-24
EA201001722A1 (ru) 2011-08-30
WO2009152079A1 (en) 2009-12-17
KR20110040819A (ko) 2011-04-20
EA018630B1 (ru) 2013-09-30
ZA201009165B (en) 2012-03-28
US8487073B2 (en) 2013-07-16
US20130288987A1 (en) 2013-10-31
US20110065652A1 (en) 2011-03-17
EP2300036B1 (en) 2017-04-05
CN102131514A (zh) 2011-07-20
IL209867A0 (en) 2011-02-28
IL209867A (en) 2015-08-31
EP2300036A4 (en) 2012-01-18
JP5628796B2 (ja) 2014-11-19
CA2727317C (en) 2015-02-17
BRPI0909947A2 (pt) 2017-06-27
CA2727317A1 (en) 2009-12-17
KR101687037B1 (ko) 2016-12-15
AU2009257631A1 (en) 2009-12-17
JP2011522839A (ja) 2011-08-04
US8729224B2 (en) 2014-05-20
EP2300036A1 (en) 2011-03-30
MX2010013436A (es) 2011-06-21
NZ590254A (en) 2012-07-27

Similar Documents

Publication Publication Date Title
CN102131514B (zh) 用于治疗性功能障碍的黑皮质素受体特异性肽
CN102459312B (zh) 黑皮质素受体特异性肽
KR101726893B1 (ko) 멜라노코르틴 수용체-특이적 펩티드
EP2440572B1 (en) Lactam-bridged melanocortin receptor-specific peptides
US20090305960A1 (en) Melanocortin Receptor-Specific Peptides for Treatment of Obesity / 669
Harris et al. Antinociceptive activity of thiazole-containing cyclized DAMGO and Leu-(Met) enkephalin analogs
WO2025245279A1 (en) Non-naturally occurring melanocortin receptor agonists and use therefore in treatment of addiction and/or pain
WO2025254700A1 (en) Orally deliverable non-naturally occurring melanocortin analogs
WO2025175226A1 (en) Orally deliverable non-naturally occurring melanocortin analogs and uses thereof for treating substance use disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140820

Termination date: 20190608